Novel pathways and therapies in experimental diabetic atherosclerosis

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 3, 2012, Pages 323-335

  Koulis, Christine ^a   De Haan, Judy B ^a   Allen, Terri J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

diabetes associated atherosclerosis; ebselen; glutathione peroxidase; HMGB1; oxidative stress; PPAR agonists; receptors for advanced glycation end products; reninangiotensin system; urotensin II

Indexed keywords

2 BROMO N [4 CHLORO 3 [(1 METHYL 3 PYRROLIDINYL)OXY]PHENYL] 4,5 DIMETHOXYBENZENESULFONAMIDE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR; ANTIOXIDANT; ASCORBIC ACID; DIPHENYL DISELENIDE; EBSELEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUTATHIONE PEROXIDASE 1; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; PALOSURAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROTEIN RAGE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; UROTENSIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES ASSOCIATED ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG HALF LIFE; DRUG MECHANISM; DYSLIPIDEMIA; GLYCATION; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; REVIEW; STROKE;

ATHEROSCLEROSIS; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; METABOLIC NETWORKS AND PATHWAYS; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RENIN-ANGIOTENSIN SYSTEM; UROTENSINS;

EID: 84858273726     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.13     Document Type: Review

References (122)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2), 434-444 (1993). (Pubitemid 23046633)
2. Candido R, Allen TJ, Lassila M et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109(12), 1536-1542 (2004). (Pubitemid 38420183)
3. Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106(2), 246-253 (2002). (Pubitemid 34761307)
4. El-Osta A, Brasacchio D, Yao D et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205(10), 2409-2417 (2008).
5. Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res. 100(10), 1415-1427 (2007). (Pubitemid 46834754)
6. Cao Z, Cooper ME, Wu LL et al. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 36(4), 561-568 (2000).
7. No authors listed. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355(9200), 253-259 (2000).
8. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 1004-1010 (2002). (Pubitemid 34286537)
9. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008). (Pubitemid 351522739)
10. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. Nephrol. Dial. Transplant. 24(5), 1663-1671 (2009).
11. Cao Z, Bonnet F, Candido R et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J. Am. Soc. Nephrol. 13(7), 1773-1787 (2002). (Pubitemid 34700602)
12. Cao Z, Kelly DJ, Cox A et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 58(6), 2437-2451 (2000).
13. Jandeleit-Dahm K, Lassila M, Davis BJ et al. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J. Hypertens. 23(11), 2071-2082 (2005). (Pubitemid 41830404)
14. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J. Clin. Invest. 88(3), 921-933 (1991).
15. Sadoshima J. Cytokine actions of angiotensin II. Circ. Res. 86(12), 1187-1189 (2000). (Pubitemid 30436655)
16. Pinaud F, Bocquet A, Dumont O et al. Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats. Hypertension 50(1), 96-102 (2007). (Pubitemid 46986016)
17. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin- angiotensin system. Circulation 109(1), 8-13 (2004). (Pubitemid 38056012)
18. Senbonmatsu T, Saito T, Landon EJ et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 22(24), 6471-6482 (2003). (Pubitemid 38009595)
19. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46(6), 1347-1354 (2005). (Pubitemid 43189734)
20. Waseda Y, Yasui M, Nishizawa Y et al. Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir. Res. 9, 43 (2008).
21. Kaschina E, Grzesiak A, Li J et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118(24), 2523-2532 (2008).
22. Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57(9), 2461-2469 (2008).
23. Koitka A, Cao Z, Koh P et al. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia 53(3), 584-592 (2010).
24. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19(3), 257-267 (1996). (Pubitemid 26070354)
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813-820 (2001). (Pubitemid 34000785)
26. Kiritoshi S, Nishikawa T, Sonoda K et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52(10), 2570-2577 (2003). (Pubitemid 37210547)
27. Ceriello A, Dello Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture; evidence linking hyperglycemia and oxidative stress. Diabetes 45(4), 471-477 (1996).
28. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 11(11-12), 524-533 (2006).
29. Tousoulis D, Antoniades C, Koumallos N et al. Novel therapies targeting vascular endothelium. Endothelium 13(6), 411-421 (2006). (Pubitemid 44941972)
30. Da Ros R, Assaloni R, Ceriello A. Antioxidant therapy in diabetic complications: what is new? Curr. Vasc. Pharmacol. 2(4), 335-341 (2004). (Pubitemid 39200183)
31. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294(1), 56-65 (2005). (Pubitemid 41002839)
32. Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 300(18), 2123-2133 (2008).
33. Marchioli R, Levantesi G, Macchia A et al. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. J. Cardiovasc. Med. 7(5), 347-350 (2006). (Pubitemid 44145638)
34. Stocker R. The ambivalence of vitamin E in atherogenesis. Trends Biochem. Sci. 24(6), 219-223 (1999). (Pubitemid 29317285)
35. Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic. Biol. Med. 28(12), 1795-1805 (2000). (Pubitemid 30628666)
36. Graham D, Huynh NN, Hamilton CA et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54(2), 322-328 (2009).
37. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother. 59(7), 365-373 (2005). (Pubitemid 41219650)
38. Lewis P, Stefanovic N, Pete J et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 115(16), 2178-2187 (2007). (Pubitemid 46659070)
39. Torzewski M, Ochsenhirt V, Kleschyov AL et al. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27(4), 850-857 (2007). (Pubitemid 46606716)
40. Blankenberg S, Rupprecht HJ, Bickel C et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. J. Med. 349(17), 1605-1613 (2003). (Pubitemid 37288568)
41. Hamanishi T, Furuta H, Kato H et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese Type 2 diabetic patients. Diabetes 53(9), 2455-2460 (2004). (Pubitemid 39145603)
42. Winter JP, Gong Y, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron. Artery Dis. 14(2), 149-153 (2003). (Pubitemid 36543417)
43. Koller LD, Exon JH. The two faces of selenium-deficiency and toxicity are similar in animals and man. Can. J. Vet. Res. 50(3), 297-306 (1986). (Pubitemid 17173696)
44. Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu. Rev. Nutr. 19, 1-16 (1999). (Pubitemid 29380594)
45. Bhabak KP, Mugesh G. Synthesis, characterization, and antioxidant activity of some ebselen analogues. Chemistry 13(16), 4594-4601 (2007). (Pubitemid 46925566)
46. Sies H. Ebselen. A selenoorganic compound as glutathione peroxidase mimic. Free Radic. Biol. Med. 14(3), 313-323 (1993). (Pubitemid 23066372)
47. Sui H, Wang W, Wang PH, Liu LS. Effect of glutathione peroxidase mimic ebselen (PZ51) on endothelium and vascular structure of stroke-prone spontaneously hypertensive rats. Blood Press. 14(6), 366-372 (2005). (Pubitemid 43135735)
48. Davis MT, Bartfay WJ. Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice. Biol. Res. Nurs. 6(1), 37-45 (2004). (Pubitemid 44005153)
49. Sies H, Masumoto H. Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. Adv. Pharmacol. 38, 229-246 (1997).
50. Chew P, Yuen DY, Koh P et al. Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 29(6), 823-830 (2009).
51. Chew P, Yuen DY, Stefanovic N et al. Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. Diabetes 59(12), 3198-3207 (2010).
52. Brodsky SV, Gealekman O, Chen J et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ. Res. 94(3), 377-384 (2004). (Pubitemid 38240730)
53. Khatri JJ, Johnson C, Magid R et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109(4), 520-525 (2004). (Pubitemid 38168516)
54. Hort MA, Straliotto MR, Netto PM, Da Rocha JB, De Bem AF, Ribeiro-Do-Valle RM. Diphenyl diselenide effectively reduces atherosclerotic lesions in LDLR -/- mice by attenuation of oxidative stress and inflammation. J. Cardiovasc. Pharmacol. 58(1), 91-101 (2011).
55. Sarma BK, Mugesh G. Glutathione peroxidase (GPx)-like antioxidant activity of the organoselenium drug ebselen: unexpected complications with thiol exchange reactions. J. Am. Chem. Soc. 127(32), 11477-11485 (2005). (Pubitemid 41176909)
56. Yamaguchi T, Sano K, Takakura K et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29(1), 12-17 (1998). (Pubitemid 28046934)
57. Schiele F. Renal dysfunction and coronary disease: a high-risk combination. J. Nephrol. 22(1), 39-45 (2009).
58. Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr. Nephrol. 24(12), 2309-2319 (2009).
59. Chander PN, Gealekman O, Brodsky SV et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J. Am. Soc. Nephrol. 15(9), 2391-2403 (2004). (Pubitemid 39159339)
60. Yoshizumi M, Kogame T, Suzaki Y et al. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br. J. Pharmacol. 136(7), 1023-1032 (2002).
61. Yoshizumi M, Fujita Y, Izawa Y et al. Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cells. Exp. Cell Res. 292(1), 1-10 (2004). (Pubitemid 38058258)
62. Ali N, Yoshizumi M, Tsuchiya K et al. Ebselen inhibits p38 mitogen-activated protein kinase-mediated endothelial cell death by hydrogen peroxide. Eur. J. Pharmacol. 485(1-3), 127-135 (2004). (Pubitemid 38134406)
63. Sarker KP, Biswas KK, Rosales JL et al. Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-2. J. Neurochem. 87(6), 1345-1353 (2003). (Pubitemid 38020569)
64. Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc. Med. 8(2), 59-64 (1998). (Pubitemid 28127945)
65. Bu DX, Rai V, Shen X et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ. Res. 106(6), 1040-1051 (2010).
66. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4(9), 1025-1031 (1998). (Pubitemid 28417334)
67. Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21(6), 905-910 (2001). (Pubitemid 34168644)
68. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. Suppl. 106, S17-S26 (2007).
69. Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53(7), 1813-1823 (2004). (Pubitemid 38857040)
70. Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 92(7), 785-792 (2003). (Pubitemid 36457644)
71. Ueno H, Koyama H, Shoji T et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in ApoE-deficient mouse. Atherosclerosis 211(2), 431-436 (2010).
72. Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis 185(1), 70-77 (2006). (Pubitemid 43117552)
73. Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in ApoE-/- mice. J. Clin. Invest. 118(1), 183-194 (2008).
74. Sun L, Ishida T, Yasuda T et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res. 82(2), 371-381 (2009).
75. Sakaguchi T, Yan SF, Yan SD et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 111(7), 959-972 (2003). (Pubitemid 36397472)
76. Zhou Z, Wang K, Penn MS et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107(17), 2238-2243 (2003). (Pubitemid 36547219)
77. Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106(22), 2827-2835 (2002). (Pubitemid 35396983)
78. Al-Mesallamy HO, Hammad LN, El-Mamoun TA, Khalil BM. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J. Diabetes Complications 25(3), 168-174 (2011).
79. Katakami N, Matsuhisa M, Kaneto H et al. Decreased endogenous secretory advanced glycation end product receptor in Type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28(11), 2716-2721 (2005). (Pubitemid 43951165)
80. Srikanth V, Maczurek A, Phan T et al. Advanced glycation end products and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging. 32(5), 763-777 (2011).
81. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93(4), 1143-1152 (2008). (Pubitemid 351519698)
82. Oozawa S, Mori S, Kanke T et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ. J. 72(7), 1178-1184 (2008). (Pubitemid 351957089)
83. Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101(7), 2652-2660 (2003). (Pubitemid 36857626)
84. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220, 35-46 (2007). (Pubitemid 350045574)
85. Yang H, Ochani M, Li J et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl Acad. Sci. USA 101(1), 296-301 (2004). (Pubitemid 38084244)
86. Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur. J. Biochem. 185(2), 303-310 (1989). (Pubitemid 19276633)
87. Kalinina N, Agrotis A, Antropova Y et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24(12), 2320-2325 (2004). (Pubitemid 39658036)
88. Inoue K, Kawahara K, Biswas KK et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc. Pathol. 16(3), 136-143 (2007). (Pubitemid 46729668)
89. Yan XX, Lu L, Peng WH et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and Type 2 diabetic patients. Atherosclerosis 205(2), 544-548 (2009).
90. Hu X, Jiang H, Bai Q et al. Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin. Chim. Acta. 406(1-2), 139-142 (2009).
91. Kanellakis P, Agrotis A, Kyaw TS et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31(2), 313-319 (2011).
92. Volz HC, Seidel C, Laohachewin D et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res. Cardiol. 105(6), 805-820 (2010).
93. Branco-Madeira F, Lambrecht BN. High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol. Med. 2(6), 193-195 (2010).
94. Bianchi ME. HMGB1 loves company. J. Leukoc. Biol. 86(3), 573-576 (2009).
95. Kim J, Sohn E, Kim CS, Jo K, Kim JS. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am. J. Nephrol. 33(6), 524-529 (2011).
96. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit. Care Med. 36(8), 2407-2413 (2008).
97. Dasu MR, Devaraj S, Park S, Jialal I. Increased Toll-like receptor (TLR) activation and TLR ligands in recently diagnosed Type 2 diabetic subjects. Diabetes Care 33(4), 861-868 (2010).
98. Pachydaki SI, Tari SR, Lee SE et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res. 82(5), 807-815 (2006). (Pubitemid 43170881)
99. Onan D, Hannan RD, Thomas WG. Urotensin II: the old kid in town. Trends Endocrinol. Metab. 15(4), 175-182 (2004). (Pubitemid 38510498)
100. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol. 18(9), 2344-2354 (2004). (Pubitemid 39215262)
101. Pearson D, Shively JE, Clark BR et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc. Natl Acad. Sci. USA 77(8), 5021-5024 (1980). (Pubitemid 11236553)
102. Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett. 457(1), 28-32 (1999). (Pubitemid 29387403)
103. Mori H, Matsunaga K, Tanakamaru Y et al. Effects of protocatechuic acid, S-methylmethanethiosulfonate or 5-hydroxy-4-(2-phenyl-(E)ethenyl)-2(5H)- furanone(KYN-54) on 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced pulmonary carcinogenesis in mice. Cancer Lett. 135(2), 123-127 (1999). (Pubitemid 29090323)
104. Itoh H, Mcmaster D, Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur. J. Pharmacol. 149(1-2), 61-66 (1988).
105. Wang ZJ, Shi LB, Xiong ZW et al. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 27(4), 858-863 (2006).
106. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176(1), 117-123 (2004). (Pubitemid 39078653)
107. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25(10), 1767-1774 (2004). (Pubitemid 39346219)
108. Ames RS, Sarau HM, Chambers JK et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401(6750), 282-286 (1999).
109. Totsune K, Takahashi K, Arihara Z et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25(10), 1809-1814 (2004). (Pubitemid 39346225)
110. Suguro T, Watanabe T, Kodate S et al. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin. Sci. (Lond.) 115(11), 327-334 (2008).
111. Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr. Pharm. Des. 10(27), 3373-3384 (2004). (Pubitemid 39276623)
112. Papadopoulos P, Bousette N, Al-Ramli W et al. Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet. Atherosclerosis 204(2), 395-404 (2009).
113. Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and Type 2 diabetes mellitus. Curr. Diabetes Rev. 3(1), 33-39 (2007). (Pubitemid 46592792)
114. Calkin AC, Forbes JM, Smith CM et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler. Thromb. Vasc. Biol. 25(9), 1903-1909 (2005). (Pubitemid 41243461)
115. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 357(1), 28-38 (2007). (Pubitemid 47026732)
116. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299(13), 1561-1573 (2008). (Pubitemid 351482795)
117. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27(7), 1647-1653 (2004). (Pubitemid 38857439)
118. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin. Drug Saf. 8(1), 15-32 (2009).
119. Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49(4), 766-774 (2006). (Pubitemid 43357552)
120. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
121. Buse JB, Bigger JT, Byington RP et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 99(12A), 21i-33i (2007).
122. Dicembrini I, Pala L, Rotella CM. From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp. Diabetes Res. 898913 (2011).